Baseline predictors of post-treatment diffusion capacity after neoadjuvant chemo-immunotherapy in non-small-cell lung cancer: development and external validation of a clinical prediction model
Interdisciplinary CardioVascular and Thoracic Surgery · 04.11.2026
DOI: 10.1093/icvts/ivag292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Interdisciplinary CardioVascular and Thoracic Surgery, online erschienen am 04.11.2026. Verfasst von Patrick Deniz Hurley und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Routine repetition of pulmonary function tests (PFTs) following neoadjuvant chemo-immunotherapy is standard but may be redundant in selected patients. We aimed to develop and externally validate a multivariable model to predict post-treatment carbon monoxide lung diffusion capacity (DLCO), with the objective of identifying patients at low predicted risk of clinically important post-treatment impairment in whom selective omission of repeat testing could potentially be considered.
Methods
A predictive model was derived from 106 patients with locally advanced non-small cell lung cancer (NSCLC) undergoing neoadjuvant chemo-immunotherapy. Multivariable regression with backward stepwise elimination was used to test candidate predictors. The model was validated on an external cohort of 60 patients. Agreement was assessed using locally weighted scatterplot smoothing (Lowess) curves and misclassification rates relative to a clinically relevant threshold of DLCO<60%.
Results
The final model retained four independent predictors: Baseline DLCO (p < 0.001), Age (p < 0.001), Programmed death-ligand 1 (PD-L1) expression (p = 0.043), and Smoking status (p = 0.10). Applied to the external validation cohort (n = 60), the model demonstrated a median predicted DLCO of 66% (IQR 59-79) versus an observed DLCO of 73% (IQR 59-83), and Lowess curves indicated a stable relationship across the data range. The model correctly identified 100% of patients with an observed post-treatment DLCO<60% by using a predicted threshold of < 65%. All patients with a predicted DLCO>65% had an observed DLCO>60%.
Conclusions
We developed and externally validated a clinical model that reliably predicts post-neoadjuvant DLCO. The model may help identify asymptomatic patients at low likelihood of a post-treatment DLCO <60% in whom repeat PFT assessment could potentially be omitted. Prospective validation is required before this approach can be recommended in routine clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
- Department of Thoracic Surgery and Lung Transplantation, Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autonoma de Madrid, Madrid, Spain.
- Department of Thoracic Surgery and Lung Transplantation, Salamanca University Hospital, Salamanca Institute of Biomedical Research (IBSAL), Salamanca, Spain.
- University of Leeds, School of Medicine, Leeds, UK.
Zitieren
APA
Hurley, P. D., Dávila, G. R., de Antonio, D. G., Gomez-Hernandez, M. T., Lodhia, J., Jimenez, M., Nardini, M., Novoa, N., Tcherveniakov, P., Teh, E., & Brunelli, A. (2026). Baseline predictors of post-treatment diffusion capacity after neoadjuvant chemo-immunotherapy in non-small-cell lung cancer: development and external validation of a clinical prediction model. Interdisciplinary CardioVascular and Thoracic Surgery. https://doi.org/10.1093/icvts/ivag292
Vancouver
Hurley PD, Dávila GR, de Antonio DG, Gomez-Hernandez MT, Lodhia J, Jimenez M, et al. Baseline predictors of post-treatment diffusion capacity after neoadjuvant chemo-immunotherapy in non-small-cell lung cancer: development and external validation of a clinical prediction model. Interdisciplinary CardioVascular and Thoracic Surgery. 2026. doi:10.1093/icvts/ivag292
BibTeX
@article{Hurley2026,
author = {Hurley, Patrick Deniz and Dávila, Guillermo Rodriguez and de Antonio, David Gómez and Gomez-Hernandez, Maria-Teresa and Lodhia, Joshil and Jimenez, Marcelo and Nardini, Marco and Novoa, Nuria and Tcherveniakov, Peter and Teh, Elaine and Brunelli, Alessandro},
title = {Baseline predictors of post-treatment diffusion capacity after neoadjuvant chemo-immunotherapy in non-small-cell lung cancer: development and external validation of a clinical prediction model},
journal = {Interdisciplinary CardioVascular and Thoracic Surgery},
year = {2026},
doi = {10.1093/icvts/ivag292}
}
EUVIMED